| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.5 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.5 |